Compare Incyte Corporation (INCY) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs NextEra Energy, Inc. — how do they compare? Incyte Corporation trades at $120.94 (market cap $24.54B), while NextEra Energy, Inc. trades at $85.5 (market cap $178.85B). The key difference: NextEra Energy, Inc. is far larger — about 7.3× Incyte Corporation's market cap, and NextEra Energy, Inc. pays a 2.91% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | NEE | |
|---|---|---|
Market Cap | $24.54B | $178.85B |
Sector | Health | Utilities |
52-Week High | $129.93 | $97.88 |
52-Week Low | $81.61 | $69.77 |
Enterprise Value | $20.04B | $286.18B |
Dividend Yield | — | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
NextEra Energy (NEE) trades at $85.45, up 0.89% today, amid a bearish technical signal but strong analyst support. The stock shows robust fundamentals with a 32.4% net income margin and 17.23% ROE, though recent cash flow volatility and rising debt-to-asset ratios (47.6% in 2025) pose concerns. Positive sentiment is driven by AI-driven power demand, highlighted by a $100 billion data center partnership with Brookfield announced on July 29, 2026.
Outlook remains favorable with a consensus price target of $100.40, implying 17.5% upside, supported by 66.66% analyst buy ratings. Key opportunities include AI infrastructure growth and dividend stability, while risks involve high capital expenditures and interest rate sensitivity. Earnings momentum is mixed, with Q1 and Q2 2026 beats offset by a Q4 2025 miss.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
